⑦【斯特兰蒂斯任命Ciancia为全球制造主管】全球第四大汽车制造商斯特兰蒂斯（Stellantis）周三宣布，Francesco Ciancia将于11月1日重新加入公司，担 任全球制造主管和斯特兰蒂斯领导力团队（SLT）的成员。 每经记者｜宋欣悦 每经编辑｜何小桃 兰素英 向江林 ①【三大期指齐涨】截至发稿，道指期货涨0.17%、标普500指数期货涨0.15%、纳指期货涨0.19%。 ②【中概股盘前涨跌不一】中概股盘前涨跌不一，阿里巴巴涨0.45%，拼多多涨0.03%，京东跌0.29%，百度跌0.39%，理想汽车涨0.95%。 ③【美国官网上线低价版Model Y和Model 3，特斯拉盘前涨1.2%】特斯拉盘前涨超1.2%。消息面上，当地时间周二，特斯拉官网更新Model Y和Model 3 标准版的订购信息。Model Y的标准版目前在美国市场起售价为3.999万美元，较此前Model Y的起售价便宜约11%。Model 3标准版起售价3.699万美元，为 特斯拉目前最便宜的车型。 ④【现货黄金站上4040美元续刷新高，黄金股盘前普涨】10月8日，现货黄金站上4040美元/盎司，续创历史新高。黄金股盘 ...

Core Insights - InnoCare Pharma Inc., a wholly-owned subsidiary of the company, has signed a licensing agreement with Zenas BioPharma, granting Zenas global development and commercialization rights for Orelabrutinib in multiple sclerosis and other non-oncology therapeutic areas [1] - Zenas will pay up to $100 million in upfront and milestone payments, with total transaction value exceeding $2 billion, including stock issuance and royalties [1] Group 1 - The agreement includes rights to two preclinical molecules: a novel oral IL-17 AA/AF inhibitor and a brain-penetrant oral TYK2 inhibitor [1] - Zenas will issue 7 million shares of common stock to the company, with additional payments tied to clinical development, registration, and commercialization milestones [1] - The company is entitled to receive tiered royalties of up to the high teens percentage on annual net sales of the licensed products [1]

Core Insights - The article highlights significant fluctuations in the market prices of silver and tin, which have impacted the stock price of Xingye Silver Tin [1] Performance - Chipone Technology expects a record high quarterly revenue of 1.284 billion yuan for Q3 [1] - Great Wall Motors reported a year-on-year sales increase of 23.29% in September [1] - Foton Motor's total vehicle sales in September grew by 6.08% year-on-year, with new energy vehicle sales increasing by 47.77% [1] - BYD experienced a year-on-year decline of 5.52% in new energy vehicle sales in September [1] - Seres saw a year-on-year sales increase of 8.33% in September [1] - BAIC Blue Valley's subsidiary reported a year-on-year sales increase of 30.15% in September [1] - Yonghe Holdings anticipates a year-on-year net profit increase of 211.59% to 225.25% for the first three quarters [1] Shareholding Changes - Huaxing Yuanchuang's shareholders plan to reduce their holdings by no more than 0.9% [1] - Ruile New Materials' shareholders intend to reduce their holdings by no more than 100,800 shares [1] Share Buybacks - Huaxin Cement plans to repurchase shares worth between 32.25 million and 64.5 million yuan [1] Contract Awards - Bomei Technology signed a contract for an offshore floating production storage and offloading vessel project, valued at approximately 190 to 240 million USD [1] - Sichuan Gold acquired exploration rights for the Kugezi-Juebei gold mine in Xinjiang [1] - Weisheng Information won projects totaling 287 million yuan, accounting for 10.45% of the company's expected revenue for 2024 [1] - Innovent Biologics' subsidiary signed a licensing agreement for the drug Orelabrutinib and two preclinical assets, with a total transaction value exceeding 2 billion USD [1] - Runjian Co. plans to bid for a land-based wind power project worth 1.753 billion yuan [1] - Xinjiang Jiaojian intends to bid for a highway construction project valued at 483 million yuan [1] Equity Changes - Delixi Holdings is planning a change in company control, leading to a stock suspension [1] - Bofei Electric plans to transfer 100% equity of its wholly-owned subsidiary Bofei New Energy [1] Other Developments - Dianguang Media holds 4.1288 million shares of Ruili Technology through Dacheng Venture Capital, representing 2.2915% of its post-issue total share capital [1] - Huaxin Cement has terminated plans for a spin-off listing of its overseas subsidiary [1] - Baili Tianheng received approval for clinical trials of BL-ARC001 for late-stage solid tumor treatment [1] - *ST Gaohong received a notice of termination of listing [1] - *ST Jianyi plans to sign an agreement to terminate the investment cooperation for the monocrystalline silicon project and deregister Jianyi Zhengyao [1]

Major Events - Delixi Co., Ltd. is planning a change in control, with stock suspension starting from October 9, 2025, for up to two trading days [1] - Sichuan Gold has won the exploration rights for the Kugez—Juebei gold mine in Xinjiang for 510 million yuan, indicating significant mining potential in a key mineral belt [1] - *ST Gaohong received a notice of termination of listing due to stock prices being below 1 yuan for 20 consecutive trading days [2] - Baili Tianheng's innovative drug BL-ARC001 has received clinical trial approval for treating advanced solid tumors, marking a significant advancement in targeted therapy [3] - Xingye Silver Tin's stock price fluctuation is attributed to significant recent price changes in its main products, silver and tin [3] Performance Overview - BAIC Blue Valley's subsidiary reported a 30.15% year-on-year increase in September sales, totaling 20,539 vehicles [4] - Seres achieved a 19.44% year-on-year increase in September sales, reaching 44,700 new energy vehicles [4] - BYD's September sales of new energy vehicles decreased by 5.52% year-on-year, totaling 396,300 vehicles, with exports of 71,256 vehicles [5] - Chipone Technology expects Q3 revenue of 1.284 billion yuan, a 119.74% increase from the previous quarter and a 78.77% increase year-on-year [5] - Yonghe Holdings anticipates a net profit increase of 448% to 507% for Q3, with projected profits of 456 million to 476 million yuan for the first three quarters [5] Major Contracts - Xinjiang Jiaojian has been awarded a 483 million yuan highway construction project [6] - Longquan Co. is a candidate for a project worth 50.76 million yuan, expected to positively impact revenue and profit [7] - Runjian Co. has secured a design and construction contract for a land-based wind power project valued at 1.753 billion yuan [8] - Innovent Biologics has signed a licensing agreement with Zenas BioPharma for the drug Obrutinib and two preclinical assets, with a total deal value exceeding 2 billion USD [8] Shareholding Changes - Huaxing Yuanchuang announced plans for its employee shareholding platforms to reduce their holdings by up to 0.9% of the company's total shares [9][10]

Group 1 - US stock index futures are showing slight gains, with Dow futures up 0.17%, S&P 500 futures up 0.15%, and Nasdaq futures up 0.19% [1] - Chinese concept stocks are mixed in pre-market trading, with Alibaba up 0.45%, Pinduoduo up 0.03%, JD down 0.29%, Baidu down 0.39%, and Li Auto up 0.95% [1] - Tesla's stock is up 1.2% in pre-market trading following the announcement of lower-priced versions of Model Y and Model 3, with Model Y starting at $39,990 (11% cheaper) and Model 3 at $36,990 [1] - Spot gold has reached $4,040 per ounce, setting a new historical high, leading to a rise in gold stocks, with GoldMining up over 16% and other gold companies rising around 3% [1] Group 2 - Innovent Biologics announced a licensing agreement with Zenas BioPharma for the product Orelabrutinib and two preclinical assets, allowing Zenas to develop and commercialize these products [2] - Stifel has raised Tesla's target price from $440 to $483 [2] - Stellantis appointed Francesco Ciancia as the global manufacturing head, effective November 1 [2] - Amazon plans to invest €1 billion (approximately $11.6 billion) in Belgium between 2025 and 2027 [2] Group 3 - OpenAI has signed deals worth approximately $1 trillion for computing power to run AI models, with partners including AMD, NVIDIA, Oracle, and CoreWeave [3]

Core Viewpoint - InnoCare Pharma Inc., a wholly-owned subsidiary of the company, has signed a licensing agreement with Zenas BioPharma, Inc. to license the drug Orelabrutinib and two preclinical assets, allowing Zenas to develop, produce, and commercialize these products [1][3]. Transaction Details - The agreement was approved by the company's board on October 7, 2025, without the need for shareholder approval [3]. - The primary licensed product, Orelabrutinib, is a late-stage clinical oral small molecule BTK inhibitor with potential best-in-class advantages, currently undergoing Phase III clinical trials for multiple sclerosis and has completed patient enrollment for Phase III registration trials in immune thrombocytopenia [3]. Company and Partner Overview - Zenas BioPharma, established in November 2019 and listed on NASDAQ in September 2024, focuses on transformative therapies for autoimmune diseases and is advancing late-stage drugs like obexelimab and Orelabrutinib [3]. - There are no affiliations or other relationships between Zenas and the company or its subsidiaries [3]. Agreement Key Terms - Zenas will pay an upfront fee of $100 million and milestone payments, with total potential payments exceeding $2 billion, including royalties of up to 10% on annual net sales of the licensed products [5][6]. - The licensing agreement will be effective upon signing and will last until the expiration of the sales rights for the licensed products, after which Zenas will receive a permanent, irrevocable license [6]. Impact on the Company - The agreement is expected to accelerate the global development and commercialization of Orelabrutinib and other pipeline products, marking a significant milestone in the company's international strategy [5]. - The transaction is not expected to affect the company's business independence or create dependency [5].

Core Insights - The company announced a licensing agreement with Zenas BioPharma, granting Zenas rights to develop, produce, and commercialize the product Orelabrutinib and two preclinical assets [1][2] Group 1: Licensing Agreement Details - The agreement includes exclusive global rights for Orelabrutinib in multiple sclerosis (MS) and exclusive rights in other non-MS and non-cancer indications outside Greater China and Southeast Asia [1] - The agreement also covers a preclinical IL-17 inhibitor and a preclinical oral TYK2 inhibitor, with exclusive rights outside Greater China and Southeast Asia for the former and global exclusive rights for the latter [1] Group 2: Financial Terms - Zenas will pay the company a $100 million upfront payment and milestone payments, including cash expected upon achieving milestones in 2026, along with 7 million shares of common stock [2] - The total potential payments from this transaction, including upfront, milestone, and commercial payments, could exceed $2 billion [2] - The company is entitled to receive tiered royalties of up to the high teens percentage based on the annual net sales of the licensed products [2]

Core Insights - 诺诚健华 and Zenas BioPharma have entered into a significant licensing agreement, granting Zenas global development and commercialization rights for 奥布替尼 in multiple sclerosis and other non-oncology indications outside Greater China and Southeast Asia [1][2] - The total transaction value exceeds $2 billion, including an upfront payment of up to $100 million, milestone payments, and the issuance of 7 million shares of Zenas common stock [1][2] - 奥布替尼 is a potential best-in-class oral BTK inhibitor with strong CNS penetration, aimed at addressing challenges in the progression of multiple sclerosis [2][3] Company Developments - Zenas will initiate a Phase III clinical trial for 奥布替尼 in primary progressive multiple sclerosis (PPMS) in Q1 2026, following a successful Phase II trial that demonstrated significant efficacy [2][3] - The collaboration is seen as a crucial milestone for 诺诚健华 in its globalization efforts, with expectations of enhancing the clinical and commercial value of 奥布替尼 [3][4] - Zenas aims to advance two additional preclinical molecules, a novel oral IL-17AA/AF inhibitor and a brain-penetrant oral TYK2 inhibitor, into clinical development by 2026 [1][4] Market Potential - 奥布替尼 has shown promising clinical data, significantly reducing the number of new lesions in patients with relapsing-remitting multiple sclerosis (RRMS) [3][4] - The strategic partnership is expected to accelerate the clinical development of 奥布替尼 and maximize its market potential, particularly in the underserved areas of PPMS and secondary progressive multiple sclerosis (SPMS) [3][4] - Zenas is positioned to become a global, integrated biopharmaceutical company focused on the development and commercialization of treatments for autoimmune diseases, leveraging its collaboration with 诺诚健华 [3][4]

Core Insights - Orelabrutinib is a potential best-in-class oral small molecule BTK inhibitor with strong CNS penetration, currently in global Phase III clinical development for progressive forms of multiple sclerosis (MS) [1][2][3] - A Phase III trial for primary progressive MS (PPMS) has been initiated, while a trial for secondary progressive MS (SPMS) is expected to start in Q1 2026 [1][2][6] - Zenas BioPharma has entered a significant licensing agreement with InnoCare Pharma, acquiring global rights for Orelabrutinib in MS and other non-oncological indications outside Greater China and Southeast Asia [1][11] Clinical Development - The Phase III trial for PPMS is a global, multicenter, randomized, double-blind, placebo-controlled study assessing the safety and efficacy of Orelabrutinib at a daily dose of 80 mg [2][6] - The SPMS Phase III trial is also designed as a global, multicenter, randomized, double-blind, placebo-controlled study, expected to start in Q1 2026 [6][14] - Previous Phase II trials demonstrated significant reductions in Gd+ T1 MRI brain lesions at 12 and 24 weeks, with sustained effects up to 96 weeks [2][4] Strategic Collaboration - The collaboration between InnoCare and Zenas is seen as a milestone in global development, enhancing the clinical and commercial value of Orelabrutinib [3][4] - Zenas aims to leverage this partnership to advance its pipeline, including two additional preclinical molecules: a novel oral IL-17AA/AF inhibitor and a CNS-penetrant oral TYK2 inhibitor, both expected to enter clinical trials in 2026 [3][7][8] Financial Terms - Under the licensing agreement, Zenas will pay InnoCare up to $100 million in upfront and milestone payments, with total transaction value exceeding $2 billion [11] - Zenas will also issue 7 million shares of common stock to InnoCare, along with tiered royalties based on annual net sales of the licensed products [11] Company Profiles - InnoCare Pharma is a biopharmaceutical company focused on innovative drug development for oncology and autoimmune diseases, with a strong pipeline of products at various stages [16] - Zenas BioPharma is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for autoimmune diseases, with a focus on Orelabrutinib and Obexelimab [17][18]

智通财经APP讯，诺诚健华(688428.SH)发布公告，公司全资子公司InnoCare Pharma Inc.与 ZenasBioPharma, Inc.(以下简称"Zenas")签署授权许可协议，将具有自主知识产权的产品奥布替尼及2项 临床前资产有偿许可给Zenas，使其可以开发、生产、商业化或以其他方式利用该等产品。 此次交易金额：Zenas将向公司支付1亿美元的首付款和近期里程碑付款，包括预计在2026年实现里程碑 时支付的现金，以及授予公司700万普通股股票，包括预计在2026年初实现里程碑时发行的股票。本次 交易首付款及近期里程碑付款，潜在的研发及注册里程碑付款，以及潜在的商业化里程碑付款总额合计 超过 20 亿美元。此外，本公司有权按许可产品年度净销售额收取最高达高百分之十几的分层特许权使 用费。 ...